Caerus Therapeutics, Inc.
Records under this name other than patents Caerus Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 6 of 6 · Back to Caerus Therapeutics, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,623,953 | Antibody Constructs and Methods of Treating Cancer Formerly held In force · High confidence | In force | High confidence | |
| US 6,376,654 | Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof Term ended Term ended Aug 13, 2019 · From the USPTO record | Term ended | Term ended Aug 13, 2019 | From the USPTO record |
| US 7,226,750 | Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof Lapsed on the fee record Ended Jun 5, 2019 · From the USPTO record | Lapsed on the fee record | Ended Jun 5, 2019 | From the USPTO record |
| US 7,691,376 | Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof Lapsed on the fee record Ended Apr 6, 2018 · From the USPTO record | Lapsed on the fee record | Ended Apr 6, 2018 | From the USPTO record |
| US 6,986,891 | Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof Lapsed on the fee record Ended Jan 17, 2018 · From the USPTO record | Lapsed on the fee record | Ended Jan 17, 2018 | From the USPTO record |
| US 7,498,129 | Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof Lapsed on the fee record Ended Mar 3, 2017 · From the USPTO record | Lapsed on the fee record | Ended Mar 3, 2017 | From the USPTO record |